A Multicenter Real-World Study of Extended-Release Methylphenidate Suspension for the Treatment of Children with Attention Deficit Hyperactivity Disorder in Fujian Province

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600121197

Enrollment

Unknown

Registered

2026-03-26

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

Experimental group:Methylphenidate Extended-Release Suspension

Eligibility

Sex/Gender

All

Age

6 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1.Age >=6 and = 6 months; 4.Legal guardians fully understand trial information, potential risks/benefits, and voluntarily provide written informed consent (participants aged >8 years must also consent).

Exclusion criteria

Exclusion criteria: 1.Hypersensitivity to methylphenidate or excipients; 2.Severe medical conditions (including epilepsy, thyroid disorders, severe cardiac disease, cardiomyopathy, arrhythmia, glaucoma, or hypertension), psychiatric disorders (schizophrenia, bipolar disorder), or substance abuse; 3.Investigator's judgment of ineligibility.

Design outcomes

Primary

Measure	Time frame
Proportion of patients with >=40% reduction in SNAP-IV total score;	—

Secondary

Measure	Time frame
Change in BRIEF total score ;Time to effective dose ;Change in DA-CAS scores;Change in WFIRS-P total score;	—

Countries

China

Contacts

Public ContactXiumei Liu

Fujian Children’s Hospital

xmliu0615@126.com+86 591 8611 2266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026